Valneva SE confirmed earnings guidance for the fiscal year 2024. For the period, expected total revenues between ?170 million and ?190 million, including: 160 million to ?180 million of sales driven by growth of Valneva?s proprietary products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.114 EUR | +2.08% | +6.03% | -12.84% |
May. 31 | Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee | MT |
May. 31 | EU regulator recommends use of Valneva's chikungunya vaccine | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.84% | 621M | |
+43.34% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024